abstract |
(57) [Summary] The present invention relates to compounds of formula (I), their stereochemically isomeric forms, their N-oxide forms, or their pharmaceutically acceptable acid addition salts, wherein R 1 is C 1 -6 alkyloxy, C 2-6 alkenyloxy or C 2-6 alkynyl - be oxy; R 2 is hydrogen, C 1-6 alkyl or C 1-6 alkyloxy; R 3 is hydrogen or halo R 4 is hydrogen or C 1-6 alkyl; R 5 is hydrogen or C 1-6 alkyl; L is C 3-6 cycloalkyl, C 5-6 cycloalkanone or C 2-6 alkynyl; or is, or, L is the formula -Al-R 6 -, Al- X-R 7, -Al-Y-C (= O) -R 9 or -Al-Y-C (= O ) -NR 11 R 12 [wherein each Al is an C 1-12 alkanediyl; and R 6 is hydrogen, cyano, C 1-6 Al Le sulfonylamino, C 3-6 cycloalkyl, C 5-6 be cycloalkanone or heterocyclic ring system,; R 7 is hydrogen, C 1-6 alkyl, hydroxy C 1-6 alkyl, C 3- 6 is cycloalkyl, or a heterocyclic ring system; X is O, S, SO 2 or NR 8 ; R 8 is hydrogen or C 1-6 alkyl; R 9 is hydrogen, C Y is NR 10 , or a direct bond; R 10 is hydrogen or C 1-6 alkyl; 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyloxy or hydroxy; R 11 and R 12 are each independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, or R 11 and R 12 combined with a nitrogen atom are optionally substituted Pyrrolidinyl, piperidinyl, piperazinyl or 4-morpholinyl ring Is a group which may 'be formed. Disclosed are methods for making the products, formulations containing the products, and their use as medicaments, particularly for treating conditions associated with impaired gastric emptying. |